 ROCKVILLE, Md., Aug. 04, 2021 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system CNS diseases, today reported financial results for the second quarter of 2021, and associated Company developments. 